FibroGen (NASDAQ:FGEN – Get Free Report) and Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.
Insider & Institutional Ownership
72.7% of FibroGen shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 2.0% of FibroGen shares are held by insiders. Comparatively, 21.6% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares FibroGen and Lisata Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| FibroGen | $147.75 million | 0.27 | -$284.23 million | ($2.45) | -0.16 |
| Lisata Therapeutics | N/A | N/A | -$20.84 million | ($2.46) | -1.23 |
Risk and Volatility
FibroGen has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and target prices for FibroGen and Lisata Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| FibroGen | 0 | 1 | 0 | 0 | 2.00 |
| Lisata Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 395.05%. Given Lisata Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than FibroGen.
Profitability
This table compares FibroGen and Lisata Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| FibroGen | -96.84% | N/A | -40.37% |
| Lisata Therapeutics | N/A | -46.48% | -41.40% |
Summary
Lisata Therapeutics beats FibroGen on 7 of the 13 factors compared between the two stocks.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
